News

Patient Power Currently, multiple myeloma (MM) is uncurable, so oncologists try to find treatment options that will control the disease. Abhinav Deol, M.D. , hematologist, medical oncologist, and member of the  Bone Marrow and Stem Cell Transplant ,  Hematology Oncology  and  Multiple Myeloma and Amyloidosis  Multidisciplinary Teams at Karmanos, explained the success rates for using CAR T cell therapy to treat MM or stem cell transplantation. Read the article here .

The Detroit News The TheraBionic P1 device is now available for patients who have advanced liver cancer and have failed first- and second-line therapies. Boris Pasche, M.D., Ph.D., FACP , president and CEO of the Barbara Ann Karmanos Cancer Institute, chair of the Department of Oncology at Wayne State University, and co-inventor of the TheraBionic P1 device, and Anthony Shields, M.D., Ph.D. , medical oncologist and member of the  Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team ,...

The Barbara Ann Karmanos Cancer Institute , the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced today that the new TheraBionic P1 device, an FDA-approved, at-home treatment , is now available to treat advanced liver cancer. Karmanos Cancer Center is the first institution worldwide to prescribe this treatment. The TheraBionic P1 device is a novel, handheld, portable device that produces low levels of 27.12 MHz radiofrequency electromagnetic fields, whic...

On Wednesday, Dec. 4, 2024, patients, survivors, and advocates gathered at Karmanos Cancer Institute in Detroit to learn about metastatic breast cancer, including initial and ongoing treatments, biomarkers and overall treatment strategies. Organized by CURE in collaboration with the Office of Cancer Health Equity and Community Engagement (OCHECE) at Karmanos, this event provided an opportunity for community members to engage with experts in metastatic breast cancer, enhancing their understanding of trea...

To celebrate Breast Cancer Awareness Month, a unique mobile entertainment company, Paint’d Party Services, decided to help bring some joy to cancer survivors by donating painting kits, an item used frequently by the Barbara Ann Karmanos Cancer Institute’s Healing Arts Program.  “Donations like these are instrumental in making sure we can help create joy in the lives of cancer survivors,” said Greg Cascione, Ph.D., philanthropy officer at Karmanos. “Being able to provide these activities and experie...

WDET A foundation will offer scholarships and internships to medical students for assistance in recruiting underrepresented and disadvantaged individuals into clinical trials. Hayley Thompson, Ph.D., associate center director of Community Outreach and Education at Karmanos Cancer Institute and faculty supervisor of Karmanos’ Office of Cancer Health Equity and Community Engagement , applauded this work and explained why it's important for patients of color to consider participating in clinical trials. Sh...

Patient Power Yusra Shao, M.D. , medical oncologist and member of the  Genitourinary Oncology Multidisciplinary Team  at Karmanos, explained how immune checkpoint inhibitors work when treating bladder cancer, and the response rate for this therapy. Read the article here .

Patient Power Amina Pervaiz, M.D. , pulmonologist and member of the Thoracic Oncology Multidisciplinary Team at Karmanos, discussed risk factors for developing a solitary pulmonary nodule. Though the majority are not cancerous, these nodules can be detected through imaging and are usually a round lesion of less than three centimeters in diameter. Read the article here .

Clinical Leader As we approach a new year, Clinical Leader asked clinical trials professionals about the success and future outlook of using decentralized clinical trials (DCT). Wasif Saif, M.D., MBBS , medical oncologist and leader of the Phase I Clinical Trials Multidisciplinary Team at Karmanos, explained how DCTs have provided access to many cancer patients, and what should be considered when designing a trial. Read the article here .

Medical Economics The conversation of cancer screenings should start with your primary care provider (PCP). Najeeb Al Hallak, M.D., MS , medical oncologist and co-leader of the Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team at Karmanos, said “PCPs are patients’ trusted first point of contact.” In this Medical Economics article, he gave PCPs recommended strategies to help patients understand their cancer risk and the consequences of delayed cancer screenings. Read the article here .